26844-12-2|Indoramin|N-[1-[2-(1H-indol-3-yl)ethyl]piperidin-4-yl]benzamide|-范德生物科技公司

Indoramin

NMR下载 COA and HPLC MSDS下载
names：
N-[1-[2-(1H-indol-3-yl)ethyl]piperidin-4-yl]benzamide
CAS号：
26844-12-2
MDL Number：
MF(分子式)： C22H25N3O MW(分子量)： 347.462
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Indoramin
英文别名	Indoramin; WY 21901; WY21901; WY-21901
CAS号	26844-12-2
SMILES	O=C(NC1CCN(CCC2=CNC3=C2C=CC=C3)CC1)C4=CC=CC=C4
Inchi	InChI=1S/C22H25N3O/c26-22(17-6-2-1-3-7-17)24-19-11-14-25(15-12-19)13-10-18-16-23-21-9-5-4-8-20(18)21/h1-9,16,19,23H,10-15H2,(H,24,26)
InchiKey	JXZZEXZZKAWDSP-UHFFFAOYSA-N
分子式 Formula	C22H25N3O
分子量 Molecular Weight	347.462
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Indoramin(CAS:26844-12-2):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Indoramin is an alpha-1 adrenergic antagonist that is commonly used as an antihypertensive agent.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Nelson RL, Thomas K, Morgan J, Jones A. Non surgical therapy for anal fissure. Cochrane Database Syst Rev. 2012 Feb 15;(2):CD00343[1]doi: 10.1002/14651858.CD003431.pub3. Review. PubMed PMID: 22336789.

[2]Kirsten R, Nelson K, Kirsten D, Heintz B. Clinical pharmacokinetics of vasodilators. Part II. Clin Pharmacokinet. 1998 Jul;35(1):9-36. Review. PubMed PMID: 9673832.

[3] Holmes B, Sorkin EM. Indoramin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and related vascular, cardiovascular and airway diseases. Drugs. 1986 Jun;31(6):467-99. Review. Erratum in: Drugs 1986 Oct;32(4):preceding 291. PubMed PMID: 3525084.

[4] Pierce DM. A review of the clinical pharmacokinetics and metabolism of the alpha 1-adrenoceptor antagonist indoramin. Xenobiotica. 1990 Dec;20(12):1357-67. Review. PubMed PMID: 1981634.

[5] Indoramin. Lancet. 1981 Jun 6;1(8232):1243-4. PubMed PMID: 6112572.

6: Seth L, Galiè N, Casebolt P, Gimenez H, Malloy M, Franciosa JA. Indoramin in heart failure: possible adverse effects on hemodynamics and exercise capacity. Clin Pharmacol Ther. 1986 Nov;40(5):567-74. PubMed PMID: 3769387.7: Bache RJ, Homans DC, Schwartz JS, Dai XZ. Differences in the effects of alpha-1 adrenergic blockade with prazosin and indoramin on coronary blood flow during exercise. J Pharmacol Exp Ther. 1988 Apr;245(1):232-7. PubMed PMID: 2896237.8: Digne-Malcolm H, Frise MC, Dorrington KL. How Do Antihypertensive Drugs Work? Insights from Studies of the Renal Regulation of Arterial Blood Pressure. Front Physiol. 2016 Jul 29;7:320. doi: 10.3389/fphys.2016.00320. eCollection 2016. Review. PubMed PMID: 27524972; PubMed Central PMCID: PMC4965470.9: Bennett JM, Weich DJ, Schoeman HS. Double-blind study comparing indoramin and propranolol in the treatment of black patients with hypertension. S Afr Med J. 1988 Dec 17;74(12):619-21. PubMed PMID: 3061032.10: Muller CA, Worthington MG, Thandroyen FT. Antiarrhythmic and metabolic effects of indoramin during acute regional ischemia and reperfusion in isolated rat heart. J Cardiovasc Pharmacol. 1990 Mar;15(3):408-13. PubMed PMID: 1691364.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开